RedHill Biopharma Ltd.
RDHL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RDHL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RDHL
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on developing and commercializing drugs for gastrointestinal, infectious diseases, and oncology, with one marketed product (Talicia) and a pipeline of clinical-stage candidates.
Key risk: Insufficient cash runway
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$4.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2025.
Tracking 2 clinical trials for RedHill Biopharma Ltd..
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on developing and commercializing drugs for gastrointestinal, infectious diseases, and oncology, with one marketed product (Talicia) and a pipeline of clinical-stage candidates.
- RedHill is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for GI diseases, infectious diseases and oncology [sec · filed 2026-04-27].
- The company commercializes Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. in partnership with Cumberland [sec · filed 2026-04-27].
- Most of RedHill's therapeutic candidates are in late-stage clinical development, but all will likely require additional successful trials before regulatory approval [sec · filed 2026-04-27].
- As of 2025-06-30, RedHill reported cash & equivalents of $2.9M, shareholders' equity of $2.1M, and total debt of $0.5M [sec].
- The company's current cash resources are not sufficient to complete the research and development of any or all therapeutic candidates and to fully support commercial operations [sec · filed 2026-04-27].
What works
- RedHill has one FDA-approved product, Talicia, which is being commercialized in the U.S. through a partnership with Cumberland, providing a revenue stream [sec · filed 2026-04-27].
- The company targets therapeutics with proven safety and efficacy profiles, which may reduce costs and time to market by re-using clinical trial designs and endpoints previously accepted by regulators [sec · filed 2026-04-27].
- RedHill has out-licensed Talicia for certain territories outside the U.S. and one candidate (RHB-102) worldwide (excluding U.S., Canada, Mexico), generating potential non-dilutive income [sec · filed 2026-04-27].
What to weigh
- RedHill's current cash resources are insufficient to complete the development of any or all therapeutic candidates and to fully support commercial operations until revenue generation [sec · filed 2026-04-27].
- None of RedHill's therapeutic candidates other than Talicia have generated revenues, and all require successful additional clinical and non-clinical trials before potential approval [sec · filed 2026-04-27].
- The company faces risks related to its ability to regain and maintain compliance with Nasdaq's minimum stockholders' equity requirement [sec · filed 2026-04-22].
- RedHill's long-term capital requirements depend on numerous factors including the progress and cost of clinical trials, and the company may need to raise significant additional capital through equity or debt financing [sec · filed 2026-04-27].
From the filings
Quoted directly from source documents.
RedHill's primary focus is on GI, infectious diseases, and oncology.
“We are a specialty biopharmaceutical company, primarily focused on U.S. development and commercialization of drugs for GI diseases, infectious diseases and oncology.”
SEC filings · April 27, 2026
Talicia is the only approved product and is commercialized with Cumberland.
“We also commercialize our GI-related product, Talicia ® (omeprazole, amoxicillin, and rifabutin) in the U.S. in partnership with Cumberland”
SEC filings · April 27, 2026
Current cash is insufficient to complete development.
“Our current cash resources are not sufficient to complete the research and development of any or all of our therapeutic candidates and to fully support our commercial operations until generation of”
SEC filings · April 27, 2026
All therapeutic candidates require additional trials before approval.
“All of our therapeutic candidates will likely require successful additional clinical and non-clinical trials before we can obtain the regulatory approvals in order to initiate commercial sales of them, if at all.”
SEC filings · April 27, 2026
Risks & what to watch (4)›
Key risks
- Insufficient cash runway — Current cash of $2.9M (as of 2025-06-30) is not enough to complete development of any candidate or support operations [sec · filed 2026-04-27].
- Dependence on additional financing — Company will need to raise significant capital through equity, debt, or non-dilutive sources to fund operations [sec · filed 2026-04-27].
- Regulatory and clinical uncertainty — All pipeline candidates require successful additional trials; FDA may not agree with proposed development plans [sec · filed 2026-04-22].
- Nasdaq compliance risk — Company faces risk of not meeting Nasdaq's minimum stockholders' equity requirement [sec · filed 2026-04-22].
What to watch
- Progress of clinical trials for opaganib and RHB-204, as they are late-stage candidates [sec · filed 2026-04-27].
- Ability to secure additional financing or out-licensing deals to extend cash runway [sec · filed 2026-04-27].
- Updates on Talicia commercialization and partnership with Cumberland [sec · filed 2026-04-27].
- Regulatory developments regarding FDA acceptance of proposed development plans [sec · filed 2026-04-22].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run RedHill Biopharma Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available RedHill Biopharma Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
N/A
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 2 sells (180d)
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$124K
| Holder | Shares | Value |
|---|---|---|
| gagnon securities llc | 88,405 | $66K |
| citadel advisors llc | 20,673 | $15K |
| xtx topco ltd | 15,163 | $11K |
| stonex group inc. | 14,481 | $11K |
| two sigma securities, llc | 13,019 | $10K |
| gamma investing llc | 6,684 | $5K |
| rhumbline advisers | 5,116 | $4K |
| federation des caisses desjardins du quebec | 3,388 | $3K |
| your advocates ltd., llp | 19 | $14 |
| smartleaf asset management llc | 5 | $4 |
Showing top 10 of 14 institutional holders of RedHill Biopharma Ltd.. Open the full 13F history after sign-in.
Short Interest
as of May 1, 2026- % of float
- 0.1%
- Days to cover
- 0.3
- Shares short
- 7,163
- Daily short volume (Jun 30, 2026)
- 27.1%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RDHL short interestFrequently asked questions
What is the AI investment thesis for RedHill Biopharma Ltd.?
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on developing and commercializing drugs for gastrointestinal, infectious diseases, and oncology, with one marketed product (Talicia) and a pipeline of clinical-stage candidates.
Who is the CEO of RedHill Biopharma Ltd.?
Mr. Dror Ben-Asher is the chief executive officer of RedHill Biopharma Ltd. (RDHL).
Where is RedHill Biopharma Ltd. headquartered?
RedHill Biopharma Ltd. (RDHL) is headquartered in Tel Aviv-Yafo, Israel.
What therapeutic areas does RedHill Biopharma Ltd. focus on?
RedHill Biopharma Ltd. develops therapies across Oncology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.